Xilio Therapeutics, Inc. (XLO)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Xilio Therapeutics, Inc. reported revenue of $43.77M, up 589.9% from the prior year. The company ran a net loss, with a net margin of -80.1%. It held $154.69M in total assets against $119.41M in total liabilities.
Key ratios (FY2025)
-95.9%
Operating margin
-80.1%
Net margin
-99.3%
Return on equity
+589.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $43.77M | $6.34M | — | — | — | — | — |
| Operating Income | -$41.98M | -$60.58M | -$79.13M | -$89.15M | -$75.04M | -$54.56M | — |
| Net Income | -$35.04M | -$58.24M | -$76.40M | -$88.22M | -$75.80M | -$55.22M | — |
| EPS (Diluted) | $-4.19 | $-15.24 | $-2.78 | $-3.22 | $-13.52 | $-105.42 | — |
| Total Assets | $154.69M | $71.08M | $60.93M | $139.16M | $218.06M | $36.32M | — |
| Total Liabilities | $119.41M | $53.48M | $24.10M | $33.52M | $32.63M | $41.60M | — |
| Shareholders' Equity | $35.27M | $17.60M | $36.83M | $105.65M | $185.43M | -$83.29M | -$29.52M |
| Cash & Equivalents | $137.53M | $55.29M | $44.70M | $120.39M | $198.05M | $19.24M | — |
| Operating Cash Flow | -$4.99M | -$18.38M | -$68.62M | -$75.72M | -$80.75M | -$36.09M | — |
| Capital Expenditures | $518.0K | $36.0K | $486.0K | $1.87M | $1.10M | $2.19M | — |
| Shares Outstanding | 4.53M | 3.27M | 27.61M | 27.43M | 27.36M | 689.9K | — |